Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $53
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $48 to $53.
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $48 to $53.